sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks LY2801653

LY2801653

CAS No.:
1206799-15-6
Catalog Number:
AG003AMN
Molecular Formula:
C30H22F2N6O3
Molecular Weight:
552.5309
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1mg
≥98%
1 week
United States
$125
- +
5mg
99%
1 week
United States
$240
- +
10mg
99%
1 week
United States
$307
- +
50mg
99%
1 week
United States
$807
- +
100mg
99%
1 week
United States
$1123
- +
Product Description
Catalog Number:
AG003AMN
Chemical Name:
LY2801653
CAS Number:
1206799-15-6
Molecular Formula:
C30H22F2N6O3
Molecular Weight:
552.5309
MDL Number:
MFCD23160048
IUPAC Name:
N-[3-fluoro-4-[1-methyl-6-(1H-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide
InChI:
InChI=1S/C30H22F2N6O3/c1-17-3-9-23(30(40)38(17)22-7-4-20(31)5-8-22)29(39)36-21-6-10-27(25(32)12-21)41-28-11-18-16-35-37(2)26(18)13-24(28)19-14-33-34-15-19/h3-16H,1-2H3,(H,33,34)(H,36,39)
InChI Key:
QHADVLVFMKEIIP-UHFFFAOYSA-N
SMILES:
Fc1ccc(cc1)n1c(C)ccc(c1=O)C(=O)Nc1ccc(c(c1)F)Oc1cc2cnn(c2cc1c1c[nH]nc1)C
UNII:
5OGS5K699E
Properties
Complexity:
1050  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
552.172g/mol
Formal Charge:
0
Heavy Atom Count:
41  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
552.542g/mol
Monoisotopic Mass:
552.172g/mol
Rotatable Bond Count:
6  
Topological Polar Surface Area:
105A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
4.7  
Literature
Title Journal
TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunological reviews 20170301
Interferon-γ regulates cellular metabolism and mRNA translation to potentiate macrophage activation. Nature immunology 20150801
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Investigational new drugs 20130801
Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity. Cancer discovery 20130701
Properties